BR9908391A - Composição antitumural contendo uma combinação sinergìstica de um derivado de antraciclina com um derivado de camptotecina - Google Patents

Composição antitumural contendo uma combinação sinergìstica de um derivado de antraciclina com um derivado de camptotecina

Info

Publication number
BR9908391A
BR9908391A BR9908391-4A BR9908391A BR9908391A BR 9908391 A BR9908391 A BR 9908391A BR 9908391 A BR9908391 A BR 9908391A BR 9908391 A BR9908391 A BR 9908391A
Authority
BR
Brazil
Prior art keywords
derivative
synergistically
combination
composition containing
tumor composition
Prior art date
Application number
BR9908391-4A
Other languages
English (en)
Inventor
Cristina Geroni
Michele Caruso
Antonino Suarato
Marina Ripamonti
Original Assignee
Pharmacia & Upjohn Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Spa filed Critical Pharmacia & Upjohn Spa
Publication of BR9908391A publication Critical patent/BR9908391A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

São apresentados o uso combinado de 4-demetoxi-3'-deamino-3'-aziridinil-4'-metanosulfonil daunorubicina ou 4-demetoxi-N,N-bis(2-cloroetil)-4'-metanosulfonil daunorubicina e um inibidor de topoisomerase I antineoplástico no tratamento de tumores e o uso de 4-demetoxi-3'deamino-3'-aziridinil-4'-metanosulfonil daunorubicina no tratamento de tumores cerebrais.
BR9908391-4A 1998-03-24 1999-03-19 Composição antitumural contendo uma combinação sinergìstica de um derivado de antraciclina com um derivado de camptotecina BR9908391A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9806324.1A GB9806324D0 (en) 1998-03-24 1998-03-24 Antitumour synergetic composition
PCT/EP1999/001897 WO1999048503A1 (en) 1998-03-24 1999-03-19 Antitumor composition containing a synergistic combination of an anthracycline derivative with a camptothecin derivate

Publications (1)

Publication Number Publication Date
BR9908391A true BR9908391A (pt) 2000-10-31

Family

ID=10829188

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9908391-4A BR9908391A (pt) 1998-03-24 1999-03-19 Composição antitumural contendo uma combinação sinergìstica de um derivado de antraciclina com um derivado de camptotecina

Country Status (29)

Country Link
US (1) US6403563B1 (pt)
EP (1) EP1067941B1 (pt)
JP (1) JP2002507571A (pt)
KR (1) KR20010034619A (pt)
CN (2) CN1150002C (pt)
AR (1) AR018166A1 (pt)
AT (1) ATE271388T1 (pt)
AU (1) AU758191B2 (pt)
BR (1) BR9908391A (pt)
CA (1) CA2324610A1 (pt)
CZ (1) CZ295368B6 (pt)
DE (1) DE69918819T2 (pt)
DK (1) DK1067941T3 (pt)
EA (1) EA003134B1 (pt)
ES (1) ES2226366T3 (pt)
GB (1) GB9806324D0 (pt)
HU (1) HUP0101615A3 (pt)
ID (1) ID26091A (pt)
IL (1) IL138035A0 (pt)
MY (1) MY133016A (pt)
NO (1) NO20004703D0 (pt)
NZ (1) NZ507570A (pt)
PL (1) PL343098A1 (pt)
PT (1) PT1067941E (pt)
SI (1) SI1067941T1 (pt)
TW (1) TW576740B (pt)
UA (1) UA63000C2 (pt)
WO (1) WO1999048503A1 (pt)
ZA (1) ZA992255B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6820065B1 (en) * 1998-03-18 2004-11-16 Ascom Hasler Mailing Systems Inc. System and method for management of postage meter licenses
GB9904387D0 (en) * 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
GB9909925D0 (en) * 1999-04-29 1999-06-30 Pharmacia & Upjohn Spa Combined preparations comprising anthracycline derivatives
GB9916882D0 (en) * 1999-07-19 1999-09-22 Pharmacia & Upjohn Spa Antitumor synergistic composition
GB9926843D0 (en) * 1999-11-12 2000-01-12 Pharmacia & Upjohn Spa Lipid complex of alkycyclines
US6627614B1 (en) * 2002-06-05 2003-09-30 Super Gen, Inc. Sequential therapy comprising a 20(S)-camptothecin and an anthracycline
EP1985286A1 (en) * 2007-04-24 2008-10-29 Biocompatibles UK Limited Microspheres for treatment of brain tumours
US8349764B2 (en) 2007-10-31 2013-01-08 Molycorp Minerals, Llc Composition for treating a fluid
US20090107925A1 (en) * 2007-10-31 2009-04-30 Chevron U.S.A. Inc. Apparatus and process for treating an aqueous solution containing biological contaminants
US20110207760A1 (en) * 2010-02-23 2011-08-25 Valery Alakhov Sn-38 compositions
EP3327148B1 (en) 2010-06-18 2021-03-17 Myriad Genetics, Inc. Methods of predicting the status of brca1 and brca2 genes in a cancer cell
DK3109325T3 (en) 2010-08-24 2019-01-28 Dana Farber Cancer Inst Inc Methods for predicting anticancer response
US9233863B2 (en) 2011-04-13 2016-01-12 Molycorp Minerals, Llc Rare earth removal of hydrated and hydroxyl species
CA2839210A1 (en) 2011-06-17 2012-12-20 Myriad Genetics, Inc. Methods and materials for assessing allelic imbalance
BR112014015152A2 (pt) 2011-12-21 2017-07-04 Myriad Genetics Inc métodos e materiais para a avaliação da perda de heterozigosidade
CA3080441A1 (en) 2012-02-23 2013-09-06 The Children's Hospital Corporation Methods for predicting anti-cancer response
US11091808B2 (en) 2012-06-07 2021-08-17 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (BRCA1/2) in human tumors
US10308986B2 (en) 2013-03-14 2019-06-04 Children's Medical Center Corporation Cancer diagnosis, treatment selection and treatment
EP2981624B1 (en) 2013-04-05 2019-12-18 Myriad Genetics, Inc. Methods for assessing homologous recombination deficiency and predicting response to cancer treatment
EP3080292B1 (en) 2013-12-09 2022-02-02 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
JP6495316B2 (ja) 2014-03-07 2019-04-03 セキュア ナチュラル リソーシズ エルエルシーSecure Natural Resources Llc 極めて優れたヒ素除去特性を備える酸化セリウム(iv)
AU2015301390B2 (en) 2014-08-15 2021-08-26 Myriad Genetics, Inc. Methods and materials for assessing homologous recombination deficiency
EP4141127A1 (en) 2021-08-30 2023-03-01 Zentrum Familiärer Brust- und Eierstockkrebs Universitätsklinik Köln Method for assessing homologous recombination deficiency in ovarian cancer cells

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9114549D0 (en) * 1991-07-05 1991-08-21 Erba Carlo Spa Mono and bis alkylamino-anthracyclines
GB9325417D0 (en) * 1993-12-13 1994-02-16 Erba Carlo Spa 3'- aziridino-anthracycline derivatives

Also Published As

Publication number Publication date
NO20004703L (no) 2000-09-20
EA200000978A1 (ru) 2001-02-26
IL138035A0 (en) 2001-10-31
AU3331499A (en) 1999-10-18
ZA992255B (en) 1999-10-05
EP1067941B1 (en) 2004-07-21
NO20004703D0 (no) 2000-09-20
DE69918819D1 (de) 2004-08-26
MY133016A (en) 2007-10-31
CN1150002C (zh) 2004-05-19
CZ20003493A3 (cs) 2001-02-14
SI1067941T1 (en) 2005-02-28
HUP0101615A2 (hu) 2001-10-28
GB9806324D0 (en) 1998-05-20
EA003134B1 (ru) 2003-02-27
AU758191B2 (en) 2003-03-20
CN1294516A (zh) 2001-05-09
UA63000C2 (en) 2004-01-15
AR018166A1 (es) 2001-10-31
CN1528334A (zh) 2004-09-15
CA2324610A1 (en) 1999-09-30
WO1999048503A1 (en) 1999-09-30
ID26091A (id) 2000-11-23
PL343098A1 (en) 2001-07-30
DE69918819T2 (de) 2005-08-18
KR20010034619A (ko) 2001-04-25
PT1067941E (pt) 2004-12-31
HUP0101615A3 (en) 2002-12-28
ATE271388T1 (de) 2004-08-15
JP2002507571A (ja) 2002-03-12
DK1067941T3 (da) 2004-11-29
ES2226366T3 (es) 2005-03-16
EP1067941A1 (en) 2001-01-17
CZ295368B6 (cs) 2005-07-13
US6403563B1 (en) 2002-06-11
NZ507570A (en) 2003-01-31
TW576740B (en) 2004-02-21

Similar Documents

Publication Publication Date Title
BR9908391A (pt) Composição antitumural contendo uma combinação sinergìstica de um derivado de antraciclina com um derivado de camptotecina
BR0008453A (pt) Composição sinergìstica anti-tumoral
IL101145A0 (en) Pharmaceutical compositions containing synergistic combinations of nucleoside derivatives
TR200002355T2 (tr) 2-(Pürin-9-il)tetrahidrofüran-3,4-diol türevleri
BR0207378A (pt) Tratamento de câncer
MY109310A (en) Antimicrobial method and formulation employing type ii endoglucosidase and antimicrobial agent
ATE231872T1 (de) Thiazolopyrimidinderivate
EP1314431A3 (en) Newcastle disease virus for therapeutic use
MY119042A (en) Dolastatin derivatives, their preparation and use
PL349028A1 (en) Cancer treatment composition and method using natural plant essential oils
TR200100054T2 (tr) Paroksetin metansülfonat
NZ507350A (en) Semi-synthetic ecteinascidins and use in treatment of tumors
AU6272598A (en) Highly lipophilic camptothecin derivatives
ES2134801T3 (es) Monohidrato de hidrocloruro de tiagabina cristalina, su preparacion y su uso.
CA2401191A1 (en) A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
SE9802937D0 (sv) Novel compounds
PT1085884E (pt) Combinacao de compostos seleniferos com gemcitabina ou mitomicina c
ATE388960T1 (de) Glykopeptidderivate mit carboxysacchariden
ZA986720B (en) Photoresponsive sunscreen compositions
PA8486601A1 (es) Formulaciones antiparasitos
BR0008454A (pt) Composição sinergìstica anti-tumoral
ES2196769T3 (es) Uso topico de loperamide para el tratamiento de infecciones microbianas.
PT1200099E (pt) Composicao sinergetica compreendendo derivados de daunorubicina e compostos antimetabolito
EA200000025A1 (ru) 13-дигидро-3'-азиридиноантрациклины
BR0009473A (pt) Tratamento de extravasamento acidental deantraciclinas

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1928 DE 18/12/2007.